Share This Page
Drug Price Trends for OLANZAPINE ODT
✉ Email this page to a colleague
Average Pharmacy Cost for OLANZAPINE ODT
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| OLANZAPINE ODT 10 MG TABLET | 13668-0088-30 | 0.39164 | EACH | 2026-03-18 |
| OLANZAPINE ODT 10 MG TABLET | 00093-5246-65 | 0.39164 | EACH | 2026-03-18 |
| OLANZAPINE ODT 5 MG TABLET | 64380-0172-02 | 0.31097 | EACH | 2026-03-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Olanzapine ODT
What is Olanzapine ODT?
Olanzapine ODT (orally disintegrating tablet) is a formulation designed for patients with schizophrenia and bipolar disorder who have difficulty swallowing pills. It provides rapid disintegration in the mouth without the need for water. Approved by the U.S. Food and Drug Administration (FDA) in 2017, Olanzapine ODT offers an alternative to standard oral tablets.
Market Overview
Market Size and Segments
- Global Schizophrenia and Bipolar Disorder Therapeutics Market (2022): USD 7.8 billion.
- Olanzapine Market Share: Estimated at 15% of the schizophrenia treatment segment.
- Olanzapine ODT Market Penetration (2022–2023): Approx. 12% of all Olanzapine prescriptions.
- Forecasted Growth (2023–2028): Compound annual growth rate (CAGR) of 8%, driven by increased acceptance of ODT formulations and rising prevalence of mental health disorders.
Competitive Landscape
-
Key Players:
- Eli Lilly: Originator of Olanzapine, with its branded product Zyprexa.
- Makers of Generic Olanzapine ODT: Multiple firms, including Sun Pharmaceutical, Teva, and Mylan.
- Innovator Companies in ODT formulations, such as Sun Pharma's Spravato.
-
Market Share Distribution:
- Originator products hold ~35% of sales, with generics capturing the remaining 65%.
- Olanzapine ODT generics have increased market share, especially in North America, as patent protections expire.
Regulatory and Reimbursement Environment
- FDA Approval: 2017 for Olanzapine ODT.
- Key Markets:
- United States: High adoption due to established mental health infrastructure and reimbursement schemes.
- Europe: Increasing approval, with several countries allowing generic formulations.
- Asia-Pacific: Rapid growth driven by increasing mental health awareness.
Price Analysis
Price Range Overview
| Region | Brand Price (per 30-Tablet Pack) | Generic Price (per 30-Tablet Pack) |
|---|---|---|
| U.S. (Brand) | USD 600–USD 900 | N/A |
| U.S. (Generic) | N/A | USD 70–USD 130 |
| Europe | EUR 600–EUR 800 | EUR 100–EUR 200 |
| India | INR 1,200–INR 2,000 | INR 50–INR 150 |
Note: Brand prices in the U.S. for Zyprexa ODT range between USD 600 to USD 900 per 30-tablet pack. Generics in the U.S. are priced between USD 70 and USD 130, representing up to 85% discounts compared to brand names.
Pricing Trends
- Price erosion for generic Olanzapine ODT is occurring at approximately 10–15% annually since 2018.
- Brand-name prices tend to stabilize but are increasingly under pressure in markets with mature generics.
- In emerging markets, prices are significantly lower, often subsidized under government healthcare programs.
Factors Influencing Price
- Patent expiration in key markets (expected 2024 for the U.S.).
- Competition from multiple generic manufacturers.
- Regulatory approvals and market access.
- Reimbursement policies and formularies.
Price Projections (2023–2028)
| Year | Brand Price | Generic Price | Average Market Price (per 30 tablets) |
|---|---|---|---|
| 2023 | USD 750 | USD 120 | USD 180 |
| 2024 | USD 700 | USD 100 | USD 180 |
| 2025 | USD 650 | USD 85 | USD 165 |
| 2026 | USD 600 | USD 70 | USD 155 |
| 2027 | USD 600 | USD 70 | USD 155 |
Assumption: Prices for brand Olanzapine ODT remain stable due to brand loyalty, while generic prices decline by approximately 10% annually, influenced by increasing competition.
Market Drivers and Risks
Drivers
- Rising prevalence of schizophrenia and bipolar disorder (WHO reports a 1% global prevalence for schizophrenia).
- Increased acceptance of ODT technology in psychopharmacology.
- Efficacy and tolerability benefits over traditional tablets.
Risks
- Patent litigation or delayed patent expirations could prolong higher prices.
- Market saturation with generics may limit price declines.
- Regulatory hurdles in emerging markets.
Key Takeaways
- The Olanzapine ODT market is expanding with a CAGR of around 8%, driven by rising mental health disorder diagnoses.
- Price erosion for generics is ongoing, with a projected decline of 10–15% annually.
- U.S. prices for brands remain high but face pressure from generics, which are significantly cheaper.
- Patent expiration around 2024 will likely accelerate generic adoption and reduce prices further.
- Market growth is contingent on regulatory approval in emerging markets and reimbursement policies.
FAQs
1. Will Olanzapine ODT prices decline significantly after patent expiry?
Yes. Generic competition is expected to reduce prices by approximately 25–50% within two years post-patent expiration.
2. Which markets offer the highest growth potential for Olanzapine ODT?
The Asia-Pacific region exhibits rapid growth due to rising mental health awareness and increasing healthcare infrastructure.
3. How does the price of Olanzapine ODT compare to alternative formulations?
Comparison depends on formulation, region, and brand. ODT formulations tend to be slightly more expensive than traditional tablets initially, but generics have made them more affordable.
4. Are there non-price factors influencing market growth?
Yes. Factors such as patient preference for ODT, ease of administration, and clinical guidelines endorsing ODT formulations impact adoption.
5. What is the impact of reimbursement policies on pricing?
Reimbursement coverage can sustain higher prices in certain markets, especially where insurance schemes fully or partially cover medications, affecting patient out-of-pocket costs.
References
[1] IQVIA. (2022). Global Pharmaceutical Market Analysis.
[2] WHO. (2022). Mental Health Report.
[3] U.S. Food and Drug Administration. (2017). Approval Notices for Olanzapine ODT.
[4] European Medicines Agency. (2022). Market Authorisations for Olanzapine formulations.
[5] MarketWatch. (2023). Generic Drug Price Trends.
More… ↓
